Author:
Holtan Shernan G.,Yu Jingbo,Paranagama Dilan,Tang Jackson,Choe Hannah K.,Naim Ahmad,Joachim Deeg H.,Galvin John
Abstract
AbstractAcute graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). This analysis of 168 patients (mean age, 54.8 years) from a multicenter, retrospective chart review describes the clinical course, treatment patterns, hospitalizations, and clinical outcomes of patients aged ≥12 years who developed grades II–IV acute GVHD after their first allogeneic HCT (January 1, 2014, to June 30, 2016) and were refractory to or dependent on corticosteroids. Between diagnosis and maximum grade (median, 6.0 days), 53.6% of patients had new organ involvement, particularly lower gastrointestinal tract acute GVHD, or an increase in acute GVHD grade. Eighty-nine patients (53.0%) received additional systemic GVHD therapy (after systemic corticosteroids) within a median of 21.0 days. Hospital readmission(s) was required for 56.5% of patients within 100 days post-HCT (mean inpatient length of readmission stay, 49.5 days); 24.4% had ≥2 readmissions within 100 days post-HCT. From the date of acute GVHD diagnosis, 70.2% of patients died at a median (interquartile range) of 117.5 (49–258) days. In summary, steroid-refractory and steroid-dependent acute GVHD is associated with a rapidly worsening clinical course that leads to high readmission and mortality rates, emphasizing the need for effective and tolerable therapies.
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference23 articles.
1. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12:443–58.
2. D’Souza A, Fretham C Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides, 2019. Available at: https://www.cibmtr.org. Accessed April 14, 2020.
3. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296–307.
4. Al Malki MM, Gendzekhadze K, Yang D, Mokhtari S, Parker P, Karanes C, et al. Long-term outcome of allogeneic hematopoietic stem cell transplantation from unrelated donor using tacrolimus/sirolimus-based GVHD prophylaxis: Impact of HLA mismatch. Transplantation. 2020;104:1070–80.
5. Ballen K, Logan BR, Chitphakdithai P, Kuxhausen M, Spellman SR, Adams A, et al. Unlicensed umbilical cord blood units provide a safe and effective graft source for a diverse population: a study of 2456 umbilical cord blood recipients. Biol Blood Marrow Transpl. 2020;26:745–57.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献